Innate Pharma (IPHA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Innate Pharma (IPHA) has a cash flow conversion efficiency ratio of -6.058x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-31.16 Million) by net assets ($5.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Innate Pharma - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how Innate Pharma's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Innate Pharma (IPHA) total liabilities for a breakdown of total debt and financial obligations.
Innate Pharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Innate Pharma ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Alligator Energy Ltd
AU:AGE
|
-0.022x |
|
Top Union Electronics
TWO:6266
|
0.064x |
|
Polski Holding Nieruchomości SA
WAR:PHN
|
0.021x |
|
GrafTech International Ltd
NYSE:EAF
|
0.080x |
|
ISC Fresh Water Investment SOCIMI SA
MC:YISC
|
0.126x |
|
HAPPY BELLY FOOD GRO.INC.
F:W3J
|
N/A |
|
Alkim Alkali Kimya AS
IS:ALKIM
|
0.070x |
|
Banco Alfa de Investimento S.A
SA:BRIV3
|
-1.114x |
Annual Cash Flow Conversion Efficiency for Innate Pharma (2005–2024)
The table below shows the annual cash flow conversion efficiency of Innate Pharma from 2005 to 2024. For the full company profile with market capitalisation and key ratios, see Innate Pharma stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $8.83 Million | $-6.90 Million | -0.781x | -2.85% |
| 2023-12-31 | $42.90 Million | $-32.56 Million | -0.759x | -114.58% |
| 2022-12-31 | $54.15 Million | $-19.15 Million | -0.354x | +34.99% |
| 2021-12-31 | $107.44 Million | $-58.46 Million | -0.544x | -63.81% |
| 2020-12-31 | $155.97 Million | $-51.81 Million | -0.332x | -306.78% |
| 2019-12-31 | $217.42 Million | $34.92 Million | 0.161x | +182.58% |
| 2018-12-31 | $167.24 Million | $-32.53 Million | -0.195x | +65.21% |
| 2017-12-31 | $85.96 Million | $-48.06 Million | -0.559x | -30.74% |
| 2016-12-31 | $86.17 Million | $-36.85 Million | -0.428x | -114.82% |
| 2015-12-31 | $72.07 Million | $207.91 Million | 2.885x | +1287.24% |
| 2014-12-31 | $74.63 Million | $-18.13 Million | -0.243x | +10.74% |
| 2013-12-31 | $40.29 Million | $-10.97 Million | -0.272x | +39.28% |
| 2012-12-31 | $23.36 Million | $-10.47 Million | -0.448x | -191.92% |
| 2011-12-31 | $26.62 Million | $12.99 Million | 0.488x | +221.55% |
| 2010-12-31 | $33.52 Million | $-13.45 Million | -0.401x | -218.54% |
| 2009-12-31 | $47.12 Million | $-5.94 Million | -0.126x | +64.67% |
| 2008-12-31 | $41.34 Million | $-14.74 Million | -0.357x | -90.56% |
| 2007-12-31 | $49.61 Million | $-9.28 Million | -0.187x | -3029.85% |
| 2006-12-31 | $56.37 Million | $360.00K | 0.006x | +101.77% |
| 2005-12-31 | $20.07 Million | $-7.25 Million | -0.361x | -- |
About Innate Pharma
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Mo… Read more